Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma

Clin Rheumatol. 1993 Mar;12(1):81-4. doi: 10.1007/BF02231564.

Abstract

We describe a male patient who developed systemic sclerosis following orchiectomy, radiotherapy and anti-androgenic treatment for prostatic adenocarcinoma. This case appears interesting as it further supports the possibility of a relationship between neoplasia and systemic sclerosis. The concurrence of scleroderma and iatrogenic hypoandrogenism suggests that hormonal influences may also play a role in the pathogenesis of this connective tissue disorder.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Androgen Antagonists / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Cyproterone Acetate / adverse effects*
  • Cyproterone Acetate / therapeutic use
  • Humans
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Orchiectomy
  • Prostatic Neoplasms / drug therapy*
  • Scleroderma, Systemic / chemically induced*
  • Scleroderma, Systemic / pathology
  • Scleroderma, Systemic / therapy

Substances

  • Androgen Antagonists
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyproterone Acetate
  • Methylprednisolone